11 results about "Synovial tissue" patented technology

The invention belongs to the field of biological medicine, and discloses a chicoric acid (CA)-loaded tetrahedral framework nucleic acid (tFNA) nano preparation for treating acute gouty arthritis. According to the preparation, tFNA formed by self-assembly is taken as a carrier, and a natural active ingredient CA is loaded to form a CA-tFNA compound. The compound overcomes the defects that CA is poor in water solubility and low in bioavailability, and existing drugs are weak in targeting and large in side effect. Through the targeted delivery and synergistic effect of tFNA, the preparation can be effectively enriched in inflammatory joints, significantly inhibit NF-kappa B signal pathways, and down-regulate the expression of key proinflammatory factors such as TNF-alpha and IL-1beta, so that joint swelling and synovial tissue damage are relieved, and repair is promoted. Experiments show that the traditional Chinese medicine composition is remarkable in curative effect and good in safety, and a novel efficient treatment strategy is provided for acute gouty arthritis.

The invention provides a muscle-bone injury area identification method and system, and relates to the technical field of muscle-bone image injury identification. The method comprises the following steps: acquiring a two-dimensional gray-scale ultrasonic image of a target muscle-bone injury area, and positioning a synovial tissue area from the two-dimensional gray-scale ultrasonic image; extracting target feature information from the synovial tissue region; and determining the inflammation activity degree of the synovial tissue according to the target feature information. According to the method, Doppler blood flow signals are completely bypassed, the rheumatism inflammation activity degree is evaluated only through rich information contained in the two-dimensional gray-scale ultrasonic image, and therefore interference of probe pressure artifacts is thoroughly avoided.

The application discloses application of TRBC2 in diagnosis of gout. In the application, patients with torn meniscus (equivalent to completely healthy synovial tissue) without a history of gout are used as a control, single-cell transcriptome analysis is carried out based on clinical biological samples, it is found that the marker TRBC2 of T cell subpopulation presents significant difference in gout patients, further Raman spectrum technology is used to find that TRBC2 protein is specifically highly expressed in synovial tissue of gouty arthritis patients, and has high diagnostic efficiency. The clinical value of TRBC2 as a marker for diagnosing gout is high, and the application prospect is wide.

This invention discloses the application of PT-129 in the preparation of drugs for treating rheumatoid arthritis (RA), belonging to the field of RA treatment. This invention is the first to demonstrate that the compound PT-129 can target and intervene in the synovial microenvironment, effectively inhibiting the abnormal activation behaviors of RA fibroblast-like synovial cells (FLS) such as proliferation, migration, and invasion, and downregulating the expression of N-cadherin and MMP3 proteins in synovial tissue. This invention provides a combined drug formulation containing PT-129 and RGFP966. This composition exhibits a significant synergistic effect in vivo, effectively relieving joint swelling, increasing bone density and trabecular bone thickness, reducing trabecular bone separation, thereby inhibiting cartilage degradation and bone destruction. This invention provides a novel targeted drug and combination therapy with definite efficacy for the clinical intervention of RA, possessing extremely high clinical application development value.

The application discloses a paeonol-loaded plant nanovesicle and application thereof in preparation of a medicine for regulating rheumatoid arthritis; the plant nanovesicle takes gardenia-derived exosome as a carrier, loads paeonol through an ultrasonic method, and is modified with a cyclic peptide RGD and a CD47 mimetic peptide on the surface, so that the plant nanovesicle can not only avoid being removed by macrophages, but also can penetrate a synovial vascular barrier and a dense extracellular matrix and be accurately delivered to an inflammatory synovial tissue, the delivery system effectively improves the stability and bioavailability of paeonol, can down-regulate a MALAT1 related signal path, inhibit abnormal activation of ERK / MAPK, and significantly reduce the expression of inflammatory factors such as IL-2, IL-6 and TNF-alpha, thereby relieving synovial inflammation of rheumatoid arthritis; the application has high targeting, long circulation, low immunogenicity and multi-dosage form adaptability, provides a novel delivery strategy of a safe and efficient active ingredient of traditional Chinese medicine, and has a wide application prospect.

The invention provides application of a composition in treatment of knee osteoarthritis. According to the invention, two rat knee osteoarthritis models (the former is called as an ACLT-induced KOA model for short, and the latter is called as a papain-induced KOA model for short) are established by respectively utilizing methods of combining anterior cruciate ligament transection (ACLT) with running and injecting papain composite L-cysteine into an articular cavity; the composition provided by the invention is used for treating two rat KOA models. Results show that the composition can improve knee joint swelling of two KOA rats, increase the pain threshold, improve the abnormal gait state, relieve cartilage injury, inhibit ACLT-induced abnormal change of a KOA rat knee joint subchondral bone microstructure and papain-induced PGE2 content in KOA rat synovial tissue, and can be used for preparing a medicine for treating osteoporosis. The level of inflammatory factors in serum and joint lavage fluid of the two KOA rats is reduced, and the discovery shows that the KOA has important application in treatment of knee osteoarthritis.

The application discloses a new application of m6A modified gene GAS6 and its receptor MERTK in rheumatoid arthritis. Multi-omics integrated analysis of synovial tissue and peripheral blood mononuclear cells of RA patients reveals common dysregulation of transcriptomics and epitranscriptomics, highlighting genes with both differential expression and m6A modification, which are enriched in processes such as phagocytosis, Th17 differentiation and cell aging. Among these genes, GAS6 shows the most significant m6A hypermethylation and expression up-regulation, and is verified as a key effector molecule interacting with MERTK / AXL receptor. Functional experiments show that GAS6 and MERTK synergistically promote the malignant phenotype of RA fibroblast-like synoviocytes, enhance their proliferation, migration, inflammatory cytokine secretion and anti-apoptotic ability.

The invention provides an extract with an acute gouty arthritis relieving effect and application thereof. The medicine is used for treating acute gouty arthritis of mammals. The plantain extract acts on an acute gouty arthritis model rat in a specific intragastric administration mode, the joint swelling degree of the model rat can be remarkably reduced, and inflammatory cell infiltration of synovial tissue is relieved.

This invention belongs to the field of traditional Chinese medicine preparation technology, and provides a traditional Chinese medicine composition with anti-inflammatory, swelling-reducing, analgesic, and joint-relieving properties, its preparation method, and its application in the preparation of drugs for treating arthralgia. The method includes the following steps: Smilax glabra, Corydalis yanhusuo (processed with vinegar), and Stephania tetrandra are pulverized, mixed, decocted with water, filtered, the filtrate is concentrated, ethanol is added to precipitate, the supernatant is collected, the ethanol is recovered and concentrated to obtain a water-extracted alcohol-immersed extract, which is then mixed with maltodextrin, wet-granulated, and dried to obtain the traditional Chinese medicine composition. The traditional Chinese medicine composition obtained by this invention is based on the principles of promoting joint mobility, reducing swelling and relieving pain. It can significantly inhibit ankle joint swelling in rats with gouty arthritis, improve local inflammatory cell infiltration, and reduce synovial tissue hyperplasia in rats with gouty arthritis.

The invention provides a PAD4 inhibitor and synovial membrane targeting peptide conjugate as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The PAD4 inhibitor and synovial membrane targeting peptide conjugate provided by the invention has a synovial membrane targeting peptide structure, and can enter and be accumulated in joint tissues through systemic circulation after administration. The linker used in the invention has a chemical bond which can be split under an acidic or oxidation condition, and can quickly release ZT-5 in a responsive manner under low pH and high oxidation conditions in an arthritis inflammation microenvironment, so that the effect of resisting rheumatoid arthritis is achieved. Meanwhile, the ZT-5 can be enriched into the facet joint cavity by utilizing the excessively proliferated synovial tissue, so that the bioavailability of the ZT-5 is improved, the administration frequency is reduced, and the defect of poor pharmacokinetic performance of a PAD4 inhibitor based on a Cl-amidine structure is overcome.

This invention discloses a method, targets, and applications for the diagnosis and treatment of hemophilic arthritis. The method includes: obtaining cartilage and synovial membrane samples from patients with hemophilic arthritis undergoing total knee arthroplasty; performing single-cell RNA sequencing, single-cell ATAC sequencing, and spatial transcriptomics analysis to determine the main cell types and key cell subpopulations constituting the microenvironment of hemophilic arthritis; identifying the molecular characteristics and differentiation processes of chondrocyte and synovial fibroblast subpopulations; measuring intercellular interactions in the knee joint microenvironment of the samples; and identifying specific regulatory transcription factors in hemophilic arthritis through paired epigenetic analysis to identify diagnostic and therapeutic targets for hemophilic arthritis. This method integrates single-cell multi-omics analysis to analyze the cellular characteristics of synovial and cartilage tissues and their interactions in the epigenetic pathogenic mechanism, identifying potential therapeutic targets.